Boehringer Ingelheim has just advanced its pan-KRAS drug into clinical testing, which the company hopes will address around 15% of all metastatic cancers. Boehringer will test the drug, BI 1701963, alone and in combination with Novartis’ MEK inhibitor Mekinist (trametinib). Preclinical data showed that the drug could potentially block tumor growth for many other G12 mutations beyond G12C as well as the G13 KRAS abnormality. With clinical trial packaging, warehousing, a depot network and logistic support, Yourway supports all phases of clinical trials.